The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

SureCN725103     1-[2-[bis(4- fluorophenyl)methoxy]ethyl]- 4...

Synonyms: cc-298, AG-G-55127, CHEBI:64086, GBR-12909, I-893, ...
This record was replaced with 3455.
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Vanoxerine


Psychiatry related information on Vanoxerine


High impact information on Vanoxerine


Chemical compound and disease context of Vanoxerine


Biological context of Vanoxerine


Anatomical context of Vanoxerine


Associations of Vanoxerine with other chemical compounds


Gene context of Vanoxerine

  • When pregnant mice from +¿- x +¿- matings were injected with the D1 receptor agonist SKF 38393, or the dopamine reuptake blocker GBR 12909 at day 19 of gestation, c-fos mRNA expression was observed in the SCN of +/+ fetuses [31].
  • In addition, GBR-12909 partially attenuated MPP+ (40 nmol)-caused a loss of striatal nerve terminal as indicated by decreases in TH and DAT immunoreactivities as well as dopamine and its metabolites levels [32].
  • Unexpectedly, hyperactivity induced by 20 mg/kg GBR 12909 was attenuated only in male COMT knockout mice, i.e., they had an inability to sustain the hyperactivity induced by DAT inhibition [33].
  • Further, when COMT knockout mice were challenged with l-dopa or a dopamine transporter (DAT) inhibitor, an accumulation of dopamine occurred and the neurochemical and locomotor effects of l-dopa and GBR 12909 were modified accordingly [34].
  • DAT-siRNA infusion in adult mice produced a significant down-regulation of DAT mRNA and protein and elicited hyperlocomotion similar, but delayed, to that produced on infusion of GBR-12909, a potent and selective DAT inhibitor [35].

Analytical, diagnostic and therapeutic context of Vanoxerine

  • Microdialysis in conjunction with thermospray tandem mass spectrometry was employed in following the time course of the experimental drug GBR-12909 in vivo [28].
  • Activation of the feedback system was accomplished by perfusion of the ACB with the DA uptake inhibitor GBR 12909 (GBR; 100 microm) [36].
  • Amphetamine-evoked dopamine release and release after injection of the selective dopamine reuptake blocker GBR 12909 were attenuated after a near-complete denervation of the SN (5 weeks after lesioning) [37].
  • Extracellular dopamine (DA) concentrations estimated by transcerebral dialysis and D1-dependent c-fos expression, as demonstrated by Fos immunohistochemistry, were studied after blockade of DA reuptake by GBR-12909 [29].
  • CONCLUSIONS: These data suggest a preferred profile of effects of GBR 12909 as an anti-cocaine pharmacotherapy [38].


  1. MPTP-induced duodenal ulcers in rat. Prevention by reuptake blockers for serotonin and norepinephrine, but not dopamine. Keshavarzian, A., Wibowo, A., Gordon, J.H., Fields, J.Z. Gastroenterology (1990) [Pubmed]
  2. Low extracellular dopamine levels are maintained in the anoxic turtle (Trachemys scripta) striatum. Milton, S.L., Lutz, P.L. J. Cereb. Blood Flow Metab. (1998) [Pubmed]
  3. 1-Methyl-4-phenylpyridinium accumulates in cerebellar granule neurons via organic cation transporter 3. Shang, T., Uihlein, A.V., Van Asten, J., Kalyanaraman, B., Hillard, C.J. J. Neurochem. (2003) [Pubmed]
  4. An animal model with relevance to schizophrenia: sex-dependent cognitive deficits in osteogenic disorder-Shionogi rats induced by glutathione synthesis and dopamine uptake inhibition during development. Castagné, V., Cuénod, M., Do, K.Q. Neuroscience (2004) [Pubmed]
  5. Critical involvement of dopaminergic neurotransmission in impulsive decision making. van Gaalen, M.M., van Koten, R., Schoffelmeer, A.N., Vanderschuren, L.J. Biol. Psychiatry (2006) [Pubmed]
  6. Individual differences in behavior following amphetamine, GBR-12909, or apomorphine but not SKF-38393 or quinpirole. Hooks, M.S., Jones, D.N., Holtzman, S.G., Juncos, J.L., Kalivas, P.W., Justice, J.B. Psychopharmacology (Berl.) (1994) [Pubmed]
  7. Effects of repeated GBR 12909 administration on brain stimulation reward. Melnick, S.M., Maldonado-Vlaar, C.S., Stellar, J.R., Trzcińska, M. Eur. J. Pharmacol. (2001) [Pubmed]
  8. Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference. Thakker, D.R., Natt, F., Hüsken, D., Maier, R., Müller, M., van der Putten, H., Hoyer, D., Cryan, J.F. Proc. Natl. Acad. Sci. U.S.A. (2004) [Pubmed]
  9. A vitamin as neuromodulator: ascorbate release into the extracellular fluid of the brain regulates dopaminergic and glutamatergic transmission. Rebec, G.V., Pierce, R.C. Prog. Neurobiol. (1994) [Pubmed]
  10. Dopamine D1 receptors synergize with D2, but not D3 or D4, receptors in the striatum without the involvement of action potentials. LaHoste, G.J., Henry, B.L., Marshall, J.F. J. Neurosci. (2000) [Pubmed]
  11. Dopaminergic therapy improves upper limb motor performance in aged rhesus monkeys. Grondin, R., Zhang, Z., Gerhardt, G.A., Gash, D.M. Ann. Neurol. (2000) [Pubmed]
  12. Differential reinforcing effects of cocaine and GBR-12909: biochemical evidence for divergent neuroadaptive changes in the mesolimbic dopaminergic system. Tella, S.R., Ladenheim, B., Andrews, A.M., Goldberg, S.R., Cadet, J.L. J. Neurosci. (1996) [Pubmed]
  13. Relationship between in vivo occupancy at the dopamine transporter and behavioral effects of cocaine, GBR 12909 [1-{2-[bis-(4-fluorophenyl)methoxy]ethyl}-4-(3-phenylpropyl)piperazine], and benztropine analogs. Desai, R.I., Kopajtic, T.A., French, D., Newman, A.H., Katz, J.L. J. Pharmacol. Exp. Ther. (2005) [Pubmed]
  14. Effects of norepinephrine and serotonin transporter inhibitors on hyperactivity induced by neonatal 6-hydroxydopamine lesioning in rats. Davids, E., Zhang, K., Kula, N.S., Tarazi, F.I., Baldessarini, R.J. J. Pharmacol. Exp. Ther. (2002) [Pubmed]
  15. Effects of GBR 12909 on locomotor activity and dopamine turnover in mice: comparison with apomorphine. Irifune, M., Nomoto, M., Fukuda, T. Eur. J. Pharmacol. (1995) [Pubmed]
  16. Mediation of dopamine D1 and D2 receptors in the effects of GBR 12909 on latent learning and locomotor activity in mice. Ichihara, K., Nabeshima, T., Kameyama, T. Eur. J. Pharmacol. (1993) [Pubmed]
  17. MPTP, MPDP+ and MPP+ cause decreases in dopamine content in mouse brain slices. Wilson, J.A., Doyle, T.J., Lau, Y.S. Neurosci. Lett. (1990) [Pubmed]
  18. Interaction of cis-(6-benzhydrylpiperidin-3-yl)benzylamine analogues with monoamine transporters: structure-activity relationship study of structurally constrained 3,6-disubstituted piperidine analogues of (2,2-diphenylethyl)-[1-(4-fluorobenzyl)piperidin-4-ylmethyl]amine. Kolhatkar, R.B., Ghorai, S.K., George, C., Reith, M.E., Dutta, A.K. J. Med. Chem. (2003) [Pubmed]
  19. Studies, using in vivo microdialysis, on the effect of the dopamine uptake inhibitor GBR 12909 on 3,4-methylenedioxymethamphetamine ('ecstasy')-induced dopamine release and free radical formation in the mouse striatum. Camarero, J., Sanchez, V., O'Shea, E., Green, A.R., Colado, M.I. J. Neurochem. (2002) [Pubmed]
  20. Hierarchical clustering analysis of flexible GBR 12909 dialkyl piperazine and piperidine analogs. Gilbert, K.M., Venanzi, C.A. J. Comput. Aided Mol. Des. (2006) [Pubmed]
  21. Effects of proposed treatments for cocaine addiction on hemodynamic responsiveness to cocaine in conscious rats. Knuepfer, M.M., Gan, Q. J. Pharmacol. Exp. Ther. (1997) [Pubmed]
  22. Modulation of [3H]mazindol binding sites in rat striatum by dopaminergic agents. Ikawa, K., Watanabe, A., Kaneno, S., Toru, M. Eur. J. Pharmacol. (1993) [Pubmed]
  23. Implication of Rho-associated kinase in the elevation of extracellular dopamine levels and its related behaviors induced by methamphetamine in rats. Narita, M., Takagi, M., Aoki, K., Kuzumaki, N., Suzuki, T. J. Neurochem. (2003) [Pubmed]
  24. Expression of a human cocaine-sensitive dopamine transporter in Xenopus laevis oocytes. Bannon, M.J., Xue, C.H., Shibata, K., Dragovic, L.J., Kapatos, G. J. Neurochem. (1990) [Pubmed]
  25. Influence of GBR 12909 and d-amphetamine on indices of catecholamine synthesis and release in rat adrenal glands. Kujacic, M., Carlsson, A. Neuropharmacology (1994) [Pubmed]
  26. Regional effects of amphetamine, cocaine, nomifensine and GBR 12909 on the dynamics of dopamine release and metabolism in the rat brain. Karoum, F., Chrapusta, S.J., Brinjak, R., Hitri, A., Wyatt, R.J. Br. J. Pharmacol. (1994) [Pubmed]
  27. Heterologous monoamine reuptake: lack of transmitter specificity of neuron-specific carriers. Di Chiara, G., Tanda, G.L., Frau, R., Carboni, E. Neurochem. Int. (1992) [Pubmed]
  28. In vivo microdialysis and thermospray tandem mass spectrometry of the dopamine uptake blocker 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)-piper azine (GBR-12909). Menacherry, S.D., Justice, J.B. Anal. Chem. (1990) [Pubmed]
  29. Combined microdialysis and Fos immunohistochemistry for the estimation of dopamine neurotransmission in the rat caudate-putamen. Morelli, M., Carboni, E., Cozzolino, A., Tanda, G.L., Pinna, A., Di Chiara, G. J. Neurochem. (1992) [Pubmed]
  30. Dopamine, but not norepinephrine or serotonin, reuptake inhibition reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates. Hansard, M.J., Smith, L.A., Jackson, M.J., Cheetham, S.C., Jenner, P. J. Pharmacol. Exp. Ther. (2002) [Pubmed]
  31. D1 receptors mediate dopamine action in the fetal suprachiasmatic nuclei: studies of mice with targeted deletion of the D1 dopamine receptor gene. Bender, M., Drago, J., Rivkees, S.A. Brain Res. Mol. Brain Res. (1997) [Pubmed]
  32. 1-methyl-4-phenylpyridinium (MPP+) decreases mitochondrial oxidation-reduction (REDOX) activity and membrane potential (Deltapsi(m)) in rat striatum. Nakai, M., Mori, A., Watanabe, A., Mitsumoto, Y. Exp. Neurol. (2003) [Pubmed]
  33. Effect of dopamine uptake inhibition on brain catecholamine levels and locomotion in catechol-O-methyltransferase-disrupted mice. Huotari, M., Santha, M., Lucas, L.R., Karayiorgou, M., Gogos, J.A., Männistö, P.T. J. Pharmacol. Exp. Ther. (2002) [Pubmed]
  34. D-amphetamine responses in catechol-O-methyltransferase (COMT) disrupted mice. Huotari, M., García-Horsman, J.A., Karayiorgou, M., Gogos, J.A., Männistö, P.T. Psychopharmacology (Berl.) (2004) [Pubmed]
  35. Global Down-Regulation of Gene Expression in the Brain Using RNA Interference, with Emphasis on Monoamine Transporters and GPCRs: Implications for Target Characterization in Psychiatric and Neurological Disorders. Hoyer, D., Thakker, D.R., Natt, F., Maier, R., Huesken, D., M??ller, M., Flor, P., VAN DER Putten, H., Schmutz, M., Bilbe, G., Cryan, J.F. J. Recept. Signal Transduct. Res. (2006) [Pubmed]
  36. Involvement of GABA and cholinergic receptors in the nucleus accumbens on feedback control of somatodendritic dopamine release in the ventral tegmental area. Rahman, S., McBride, W.J. J. Neurochem. (2002) [Pubmed]
  37. In vivo characterization of somatodendritic dopamine release in the substantia nigra of 6-hydroxydopamine-lesioned rats. Sarre, S., Yuan, H., Jonkers, N., Van Hemelrijck, A., Ebinger, G., Michotte, Y. J. Neurochem. (2004) [Pubmed]
  38. Effects of GBR 12909, WIN 35,428 and indatraline on cocaine self-administration and cocaine seeking in rats. Schenk, S. Psychopharmacology (Berl.) (2002) [Pubmed]
WikiGenes - Universities